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INTRODUCTION
Acinic cell carcinoma (AcCC) is a rare salivary gland malignancy 
that accounts for approximately 12% to 17% of all salivary gland 
cancers. Females display a higher incidence of this disease, with 
a female-to-male incidence ratio of 1.36:1, and its overall inci-
dence is increasing, especially among males [1]. This neoplasm 
mostly presents as a slow-growing parotid mass, and is generally 
considered to be a low-grade malignancy. Surgery alone is gen-
erally linked to excellent long-term disease control [2]. However, 
in a subset of patients, AcCC exhibits aggressive features such as 
recurrence, distant metastasis, and mortality. Previous research 
pointed to aggressive histologic variants of AcCC, a minority of 
which could transform into high-grade malignancy, but the clini-
copathologic predictive factors of a poor prognosis have not yet 
been fully elucidated, due to the rarity of the disease and the 
heterogeneity of treatments in study populations. Adjuvant ra-
diotherapy is generally recommended for cases with adverse 
pathologic features, but the benefits of postoperative radiothera-
py for disease control and/or survival in patients with low-grade 
salivary gland cancers remain controversial [3-6]. The purpose of 
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Objectives. In subset of patients, acinic cell carcinoma (AcCC) exhibits aggressive features such as recurrence, distant me-
tastasis, and mortality. This study aimed to investigate clinicopathologic factors influencing patients’ prognosis and to 
identify adverse features predictive of an unfavorable prognosis.
Methods. Between January 2000 and December 2016, 59 patients with AcCC were enrolled in this study. 
Results. The patients’ 5-year overall survival rate was 93.3%, and their 5-year recurrence-free survival rate was 80.5%. 
During the study period, recurrence occurred in 10 patients. The mean time to recurrence after surgery was 26 
months (range, 5–60 months). During the study period, three patients died from the disease. Univariate analysis 
showed that sex, surgical extent, extranodal extension, T classification, and TNM stage were significantly associated 
with disease recurrence. Multivariate analysis showed that, among the clinicopathologic factors included in the analy-
sis, only TNM stage displayed a statistically significant correlation with disease recurrence. 
Conclusion. Surgical treatment alone yielded good results for AcCC, and additional treatment did not affect the recurrence-
free survival rate or the overall survival rate, even when the resection margin was less than 1 mm. Other pathologic 
factors did not show prognostic significance for disease recurrence or death. 
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this study was to investigate the treatment outcomes of patients 
with AcCC of the parotid gland, to analyze the clinicopathologic 
factors that influenced treatment outcomes, and to identify ad-
verse features predictive of an unfavorable prognosis. We also 
assessed the influence of surgical extent and adjuvant therapy 
on treatment outcomes in patients with AcCC of the parotid 
gland.
MATERIALS AND METHODS
The Institutional Review Board of Yonsei University approved 
this study (IRB No. 2017-0037-001) and Informed consent was 
waived. 
Among patients who were diagnosed with AcCC and visited 
our hospital from January 2000 to December 2016, we enrolled 
59 patients who underwent surgery as an initial treatment and 
conducted a retrospective review of their medical records. Inclu-
sion criteria were as follows: (1) patients diagnosed with AcCC 
of the parotid gland after surgery; (2) patients who underwent 
surgery with curative intent as initial treatment; and (3) patients 
who underwent at least 12 months of follow-up. Exclusion crite-
ria were as follows: (1) distant metastasis at the time of diagno-
sis; and (2) previous surgery or radiotherapy on the head and 
neck. Our study included 29 males and 30 females. The patients’ 
ages ranged from 6 to 72 year, and the mean age was 41.2 years. 
The relationship between clinicopathologic parameters (sex, age, 
tumor size, TNM stage, surgical extent, adjuvant radiotherapy, 
resection margin status, intraglandular lymph node metastasis, 
and histologic grade) and unfavorable outcomes (recurrence or 
death) were analyzed. Pathologic TNM stage was determined 
based on pathology reports using the 8th American Joint Com-
mittee on Cancer Staging Manual. Inclusion criteria were as fol-
lows: histologically diagnosed as only AcCC, and cases with suf-
ficient clinicopathological information available from medical 
records. Exclusion criteria were as follows: distant metastasis at 
the time of presentation, and loss to follow-up.
The extent of parotidectomy was determined according to the 
location and extent of the disease, as determined by preoperative 
imaging studies. The extent of surgery was defined as superficial 
or total parotidectomy. Elective neck dissection was not usually 
performed in the absence of cervical lymph node metastasis; and, 
if necessary, selective neck dissection, including levels II and III, 
was performed. In the case of cervical lymph node metastasis, 
modified radical neck dissection, including levels II–V, was per-
formed. In postoperative pathologic examination, adjuvant treat-
ment was considered in cases of advanced T stage, positive mar-
gin, extracapsular nodal spread, multiple metastatic lymph nodes, 
lymphovascular invasion, and perineural invasion.
Patients’ clinical information, tumor location and stage, patho-
logic findings, recurrence, date of recurrence, recurrence pattern, 
death events, date of death, and cause of death were collected 
and analyzed. Patients were categorized into either favorable or 
unfavorable groups according to their prognosis. We defined un-
favorable group as local, regional, distant failure cases, or death 
related to the disease during follow-up period. For unfavorable 
group, available pathology materials, tumor growth pattern, tu-
mor border, peritumoral stroma, cytological features, tumor ne-
crosis, lymphovascular invasion, perineural invasion, and high 
grade transformation were additionally reviewed. Univariate 
and multivariate analyses were performed to evaluate the prog-
nostic factors affecting patients’ survival. Chi-square or Fisher’s 
exact tests were used to evaluate the differences in categorical 
variables between two independent groups. An independent 
two-sample t-test was used to assess differences in continuous 
variables between the two independent groups. Multivariate lo-
gistic regression analysis was performed to model dichotomous 
variables. Kaplan-Meier curves were used to analyze disease-free 
survival, and survival outcomes were assessed using log-rank 
test. A P-value <0.05 indicated statistical significance. Statistical 
analyses were performed using SPSS ver. 18.0 (SPSS Inc., Chi-
cago, IL, USA). 
RESULTS
Fifty-nine patients were enrolled in this study. AcCC was found 
in the left parotid gland in 24 patients and in the right parotid 
gland in 35 patients. All patients underwent surgery with cura-
tive intent as the initial treatment; 31 underwent superficial pa-
rotidectomy and 28 underwent total parotidectomy. Elective se-
lective neck dissection, including levels II and III, was performed 
in eight patients, and two patients received therapeutic modified 
radical neck dissection. Twenty-eight patients had TNM stage I 
disease, 16 patients had stage II disease, six patients had stage III 
disease, and nine patients had stage IV disease (Table 1).
The mean follow-up period was 52 months (range, 8–203 months). 
The 5-year overall survival rate was 93.3%, and the 5-year re-
currence-free survival rate was 80.5% (Fig. 1). During the study 
period, recurrence took place in 10 patients (eight cases of local 
recurrence, three cases of regional recurrence, and two cases of 
distant metastasis). The mean time to recurrence after surgery 
  The 5-year overall survival rate in 59 patients with acinic cell 
carcinoma (AcCC) was 93.3%, and their 5-year recurrence-
free survival rate was 80.5%.
  Multivariate analysis showed that only TNM stage displayed a 
statistically significant correlation with disease recurrence.
  Surgical treatment alone yielded good results for AcCC, and 
additional treatment did not affect the recurrence-free survival 
rate or the overall survival rate.
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was 26 months (range, 5–60 months). Nine patients experienced 
recurrence within 36 months after surgery, except for one patient 
who experienced recurrence 60 months postoperatively. Nine pa-
tients underwent salvage surgery and one patient received con-
current chemoradiotherapy to control recurrent disease. During 
Table 1. Clinical information of all patients with acinic cell carcinoma 
of the parotid gland
Variable Value (n=59)
Age (yr) 41.2 (6–72)
Sex
   Male 29 (49.2)
   Female 30 (50.8)
Lesion side
   Left 24 (40.7)
   Right 35 (59.3)
   Bilateral 0 
Extent of surgery for parotid
   Superficial 31 (52.5)
   Total 28 (47.5)
Neck dissection
   None 49 (83.0)
   SND including II–III  8 (13.6)
   MRND 2 (3.4)
Adjuvant therapy
   No 43 (72.9)
   Yes 16 (27.1)
pT classification
   1 23
   2 27
   3   2
   4   7
pN classification
   0 54
   1   3
   2   2
TNM stage
   I 28 (47.5)
   II 16 (27.1)
   III  6 (10.2)
   IV  9 (15.3)
Recurrence 
   Local 8 11 (18.6)
   Regional 3 5 (8.5)
   Distant metastasis 2 2 (3.4)
Values are presented as mean (range) or number (%).
SND, selective neck dissection; MRND, modified radical neck dissection.
Fig. 1. Five-year overall survival (A) and 5-year recurrence-free sur-
vival (B) among all patients. 
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Fig. 2. Disease recurrence and death events in patients with acinic cell carcinoma of the parotid gland after surgery. (A) Disease recurrence 
and death events. (B) Disease recurrence pattern.
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the study period, only three patients died due to the disease 
(Fig. 2).
A univariate analysis was conducted of the clinicopathologic 
factors associated with recurrence (Table 2). Sex (P=0.041), sur-
gical extent (P=0.020), extranodal extension (P<0.001), T clas-
sification (P=0.023), and TNM stage (P<0.001) showed statisti-
cally significant associations with disease recurrence. Age, resec-
tion margin status, lymph node metastasis, lymphovascular inva-
sion, perineural invasion, and adjuvant treatment were not sig-
nificantly correlated with disease recurrence. Kaplan-Meier anal-
ysis was used to evaluate the 5-year recurrence-free survival rate. 
Statistically significant differences in the survival rate were found 
Table 2. Univariate analysis of clinical variables for RFS 
Variable
No. of 
patients (%)
No. of 
events
5-Year 
RFS (%)
P-value
Age (yr) 0.818
   <60 48 (81.4) 8 81.2
   ≥60 11 (18.6) 2 77.1
Sex 0.041
   Male 29 (49.2) 8 68.9
   Female 30 (50.8) 2 92.6
Surgical extent 0.020
   Superficial 31 (52.5) 2 93.1
   Total 28 (47.5) 8 64.8
Resection margin 0.583
   Positive 4 (6.8) 1 75.0
   Negative 55 (93.2) 9 81.1
Margin status 0.112
   Positive 4 (6.8) 1 75.0
   Close margin (<1 mm) 18 (30.5) 5 63.6
   Negative 37 (62.7) 4 88.1
LN metastasis 0.329
   Yes 4 (6.8) 1 75.0
   No 55 (93.2) 9 81.3
ENE <0.001
   Yes 1 (1.7) 1 0
   No 58 (98.3) 9 82.0
LVI 0.641
   Yes 4 (6.8) 1 66.7
   No 55 (93.2) 9 81.3
PNI 0.249
   Yes 2 (3.4) 1 50.0
   No 57 (96.6) 9 81.9
Adjuvant Tx 0.659
   Yes 16 (27.1) 2 85.7
   No 43 (72.9) 8 78.6
T classification 0.023
   1 & 2 50 (84.7) 5 86.4
   3 & 4 9 (15.3) 4 50.0
TNM stage <0.001
   I & II 44 (74.6) 2 92.8
   III & IV 15 (25.4) 7 40.6
RFS, recurrence-free survival; LN, lymph node; ENE, extranodal exten-
sion; LVI, lymphovascular invasion; PNI, perineural invasion; Tx, treatment.
Fig. 3. Kaplan-Meier analysis of 5-year recurrence-free survival ac-
cording to sex (A), TNM stage (B), and T classification (C).
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according to sex, TNM stage, and T classification (Fig. 3). The clin-
icopathologic factors related to recurrence were then entered 
into a multivariate analysis. Of the clinicopathologic factors in-
cluded in the analysis, only TNM stage showed a statistically sig-
nificant correlation with disease recurrence (P=0.018) (Table 3).
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Clinicopathologic factors associated with death events were 
analyzed by univariate analysis (Table 4). There was a statistical-
ly significant correlation between age (P=0.020), perineural in-
vasion (P=0.005), T classification (P=0.006), TNM stage (P=0.001), 
and death. Sex, surgical extent, resection margin, lymph node 
metastasis, extranodal extension, lymphovascular invasion, and 
adjuvant treatment were not correlated with death. Kaplan-Meier 
analysis was used to examine the 5-year overall survival rate of 
patients, and statistically significant differences were found ac-
cording to TNM stage and T classification (Fig. 4). Clinicopatho-
logic factors related to death events were analyzed by multivari-
ate analysis, and no statistically significant correlations were 
found (Table 3).
Surgical margin status
A positive margin was defined as the presence of cancer cells in 
the margin of the resected specimen, and a negative margin was 
defined as the absence of cancer cells. Positive margins were re-
ported in four patients, and negative margins were reported in 
the remaining 55 patients. A statistical analysis of the relation-
ship of margin status with recurrence and death events showed 
no significant correlation. Due to the presence of the facial nerve 
within the parotid gland, surgeons often receive a pathologic re-
port with a margin of less than 1 mm, known as an “abutting” 
margin status [7]. When these “abutting” margins were regarded 
as positive, a positive margin was found to be significantly corre-
lated with disease recurrence in the univariate analysis (P=0.038), 
but not in the multivariate analysis.
Surgical extent and adjuvant treatment
We classified the extent of surgery as superficial parotidectomy 
or total parotidectomy, and evaluated possible relationships as-
sociated with disease recurrence or death. Surgical extent was 
significantly correlated (P=0.020) with disease recurrence in the 
univariate analysis, but not in the multivariate analysis. There 
were no statistically significant correlations between adjuvant 
treatment and disease recurrence or patient mortality.
Unexpected malignancy
All patients underwent fine-needle aspiration cytology (FNAC) 
before surgery. Forty-five patients were suspected to have AcCC 
or malignancy according to the preoperative cytology report, but 
the remaining 14 patients underwent surgery without suspicion 
of malignancy before surgery. All tumors in these patients were 
stage T1 or T2, and a negative margin was obtained in 13 of these 
Table 3. Multivariate Cox regression analysis for RFS and OS adjust-
ing for various prognostic factors
Factor Hazard ratio 95% CI P-value
Associated with RFS
   Sex   0.402 0.077–2.094 0.279
   Resection margin   2.358  0.419–13.274 0.331
   Extranodal extension 115.635 0.000–1.123 0.958
   PNI   0.500 0.047–5.315 0.565
   T classification   0.654 0.365–1.170 0.152
   TNM stage   2.312 1.156–4.623 0.018
Associated with OS
   Age   1.204  0.579–2.503 0.619
   Sex   0.004 0.000–1055 0.679
   LVI  12.571  0.000–4.998 0.982
   PNI  65.845  0.000–1.592 0.971
   T classification   7.385  0.000–4.684 0.894
   TNM stage   1.723  0.000–1735 0.954
RFS, recurrence-free survival; OS, overall survival; CI, confidence interval; 
PNI, perineural invasion; LVI, lymphovascular invasion.
Table 4. Univariate analysis of clinical variables for OS
Variable
No. of 
patients (%)
No. of 
events
5-Year 
OS (%)
P-value
Age (yr) 0.020
   <60 48 (81.4) 8  97.9
   ≥60 11 (18.6) 2  68.2
Sex 0.080
   Male 29 (49.2) 8  86.8
   Female 30 (50.8) 2 100
Surgical extent 0.446
   Superficial 31 (52.5) 2  96.8
   Total 28 (47.5) 8  88.4
Resection margin 0.608
   Positive 4 (6.8) 1 100
   Negative 55 (93.2) 9  92.6
Margin status 0.829
   Positive 4 (6.8) 1 100
   Close margin (<1 mm) 18 (30.5) 5  66.7
   Negative 37 (62.7) 4  94.6
LN metastasis 0.720
   Yes 4 (6.8) 1 100
   No 55 (93.2) 9  93.0
ENE 0.790
   Yes 1 (1.7) 1 100
   No 58 (98.3) 9  93.1
LVI 0.107
   Yes 4 (6.8) 1  66.7
   No 55 (93.2) 9  96.3
PNI 0.005
   Yes 2 (3.4) 1 0
   No 57 (96.6) 9  96.5
Adjuvant Tx 0.306
   Yes 16 (27.1) 2 100
   No 43 (72.9) 8  91.0
T classification 0.006
   1 & 2 50 (84.7) 5  96.2
   3 & 4 9 (15.3) 4  77.8
TNM stage 0.001
   I & II 44 (74.6) 2 100
   III & IV 15 (25.4) 7  71.8
OS, overall survival; LN, lymph node; ENE, extranodal extension; LVI, lym-
phovascular invasion; PNI, perineural invasion; Tx, treatment.
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Table 5. Pathologic features for patients group with disease recurrence
Case Growth pattern Major pattern Capsule invasion Stroma High grade transformation Necrosis
1 Multinodular Solid Yes Sclerosis No No
2 Multinodular Solid No Sclerosis No No
3 Single round Solid Yes Sclerosis No No
4 Multinodular Papillocystic Yes Sclerosis No No
5 Single round Papillocystic Yes None No No
6 Infiltrative Microcystic Yes Sclerosis No No
7 Single round Papillocystic No None No No
8 Multinodular Solid No Sclerosis No No
9 Single round Papillocystic No Sclerosis No Yes
10 Single round Papillocystic Yes Sclerosis No No
Fig. 4. Kaplan-Meier analysis of 5-year overall survival according to TNM stage (A) and T classification (B).
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14 patients after surgery. Only two patients experienced recur-
rence during the study, but they survived without residual dis-
ease after salvage surgery (one local recurrence and one regional 
recurrence).
Salvage treatment
Among the 10 patients who had disease recurrence, salvage sur-
gery was performed in eight patients, followed by disease-free 
survival. The remaining two patients had both distant metastasis 
and loco-regional recurrence; both received concurrent chemo-
therapy, and one died during the study period.
Pathologic features specific to unfavorable outcomes
The pathologic features associated with unfavorable outcomes, 
based on the available pathology materials (n=10), are summa-
rized in Table 5. Within this group, pathologic features varied in 
terms of tumor growth pattern, tumor border, peritumoral stroma, 
cytological features, tumor necrosis, and high-grade transforma-
tion. Interestingly, high-grade transformation was not observed 
in any cases in our study, and other histopathologic features were 
likewise not found to be characteristic of unfavorable outcomes.
DISCUSSION
AcCC is a rare disease entity that occurs in the major salivary 
glands, accounting for about 10% of salivary gland tumors [8]. 
It occurs in relatively young patients, and shows less aggressive 
features than other salivary carcinomas. AcCC is generally known 
as a low-grade salivary gland tumor, but its prognosis is some-
times poor in a subset of AcCC patients in whom pathologically 
high-grade features are observed [9]. Neskey et al. [10] reported 
that several adverse prognostic factors, including sex, age, a tumor 
size larger than 3 cm, and distant metastasis, were associated 
with poorer survival. Although adjuvant radiotherapy is generally 
recommended in patients with several adverse features, the indi-
cations for adjuvant treatment in patients with AcCC have not 
yet been established [11]. In particular, whether adjuvant treat-
ment is indicated in young patients with a long life expectancy 
after treatment is an important issue, as quality of life can dete-
riorate after intensive treatment with radiotherapy or concurrent 
chemoradiotherapy.
Furthermore, more than 90% of AcCCs are known to occur 
in the parotid glands, while fewer than 10% occur in the minor 
salivary gland, and the condition rarely occurs in the subman-
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dibular gland. Different concerns are associated with the surgi-
cal treatment of carcinoma arising from the parotid gland, com-
pared to cancer in the minor salivary or submandibular gland. 
Since the facial nerve is present inside the parotid gland, and the 
anatomy around the parotid gland is complex, it is challenging 
to obtain a sufficient safety margin when the tumor is resected. 
As the surgeon should both preserve the facial nerve and extir-
pate the tumor with a sufficient margin during the operation, a 
dilemma is encountered in real clinical settings. Accordingly, sal-
ivary gland carcinoma—although histologically a single type of 
carcinoma—has unique clinical characteristics according to the 
gland in which it originates. Therefore, this study focused only 
on AcCCs in the parotid gland.
In our study, the mean age of patients with AcCC was 41 years 
(6–72 years). The 5-year overall survival rate was 93%, and the 
5-year disease-free survival rate was 80%. No statistically signif-
icant correlations were found between death events and any clin-
icopathologic factors, and TNM stage was the only parameter 
significantly associated with disease recurrence. During the study 
period, 10 patients experienced disease recurrence, of whom eight 
patients survived in a disease-free state after successful salvage 
surgery. Even in cases of recurrence, most of the patients (80%) 
were able to undergo salvage surgery, and the oncologic results 
were also favorable after salvage treatment. 
In this study, 18 patients showed a resection margin of less 
than 1 mm, also known as an “abutting” margin status. Eight of 
these patients received adjuvant radiotherapy, and the remaining 
10 patients did not receive adjuvant therapy; however, there was 
no significant difference in disease recurrence or mortality be-
tween patients who received adjuvant treatment and those who 
did not. Generally, from the perspective of an oncologic surgeon, 
a resection margin of less than 1 mm is regarded as a positive 
margin and adjuvant therapy should be considered. However, 
for AcCC, it was confirmed that local control was good without 
adjuvant therapy in cases with an “abutting” margin.
In salivary gland cancer, histologic grade and tumor type are 
important prognostic parameters, together with other risk factors 
such as TNM stage, resection margin status, and lymph node me-
tastasis. Biron et al. [3] performed a retrospective survival analysis 
of 2,061 patients based on the Surveillance, Epidemiology, and 
End Results registry, and suggested that histologic grade is a stron-
ger predictor of survival than TNM classification in AcCC patients. 
However, a standard grading scheme for salivary gland cancer 
remains to be established, and adverse pathologic factors predic-
tive of prognosis also remain unclear. Therefore, in this study, we 
intensively investigated the pathologic factors that could predict 
the prognosis of AcCC patients; however, no pathologic feature 
showed a significant relationship with disease recurrence or death. 
Interestingly, high-grade transformation findings known to be as-
sociated with a poor prognosis were not observed in our study.
FNAC is usually performed before surgery in patients with 
salivary gland tumors to determine whether the tumor is malig-
nant. However, a low-grade salivary gland malignancy may be 
unexpectedly diagnosed as malignant on a permanent patholog-
ic examination after surgery, inconsistent with the results of pre-
operative FNAC. In these unexpected cases, the surgical margin 
status might be inappropriate. Especially in parotid surgery, 
since the facial nerve runs within the parotid gland, the tumor 
could be marginally excised to preserve the facial nerve. In cases 
in which the tumor is excised marginally without a sufficient 
safety margin, the surgeon must consider whether to perform a 
completion parotidectomy or to perform adjuvant treatment. To 
overcome the limitation of the false-negative rate of FNAC, Cha 
et al. [12] reported that intraoperative frozen section examina-
tions may be helpful in the diagnosis of AcCC of the parotid 
gland. However, intraoperative frozen sections are not usually 
performed during parotid surgery in real clinical situations. In 
our study, 14 patients (23.7%) were unexpectedly diagnosed 
with AcCC after surgery, inconsistent with their preoperative 
FNAC results. Of these, 12 patients underwent only superficial 
parotidectomy, while the remaining two patients received total 
parotidectomy. Of these 12 patients, only one patient received 
adjuvant radiotherapy. Nonetheless, disease only recurred in 
two patients during the study period, irrespective of the extent 
of surgery and adjuvant therapy, and the two patients with re-
current disease underwent successful salvage surgery and sur-
vived in a disease-free state.
Based on our results, surgical treatment alone yielded extreme-
ly good results for AcCC, and surgical extent and adjuvant ther-
apy did not affect the disease-free survival or overall survival 
rates, even when the resection margin was less than 1 mm. The 
risk of disease recurrence was only higher in AcCC with an ad-
vanced TNM stage, in which more aggressive treatment, such as 
total parotidectomy or adjuvant radiotherapy, may be consid-
ered to prevent disease recurrence.
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